A new congressional report concluded that Emergent BioSolutions (NYSE:EBS) attempted to hide evidence related to quality problems before informing the FDA that 15 million COVID-19 vaccines were contaminated. Prepared for Rep. Carolyn Maloney (D-NY) and James E. Clyburn (D-SC), the report from the House and the Select Subcommittee on the Coronavirus Crisis scrutinizes the quality controls in…
Johnson & Johnson reaches opioid settlement with Alabama
On the heels of announcing a $99 million opioid settlement with West Virginia, Johnson & Johnson (NYSE:JNJ) has reached a similar deal worth $77 million with the state of Alabama. The agreement removes J&J from cases filed in the state. The agreement did not involve an admission of liability or wrongdoing. In January, J&J reached…
Johnson & Johnson rises on mixed bag Q1, increased 2022 guidance
Johnson & Johnson (NYSE:JNJ) shares ticked up today on first-quarter results that were mixed compared to the consensus forecast. The New Brunswick, New Jersey-based company posted profits of $5.1 billion, or $1.93 per share, on sales of $23.4 billion in the first quarter for a 16.9% bottom-line slide on sales growth of nearly 5%. Get the…
Johnson & Johnson announces opioid settlement with West Virginia
Johnson & Johnson (NYSE:JNJ) has agreed to pay $99 million to put opioid-related claims in the State of West Virginia to bed. The state has removed J&J from an ongoing trial in Kanawha County. West Virginia’s attorney general, Patrick Morrisey, concluded that state’s decision not to join a nationwide settlement was worthwhile because the state received…
How medtech and pharma are responding to Russia’s invasion of Ukraine
Medtech and pharma companies continue to support Ukraine relief efforts following Russia’s invasion. Previously, the World Health Organization announced that it was sending “essential medical supplies” to Ukraine — including its first shipment of 36 metric tons of supplies for trauma care and emergency surgery and other health supplies — to meet the needs of more than…
Johnson & Johnson inks agreement to have its COVID-19 vaccine manufactured in Africa
Johnson & Johnson (NYSE:JNJ) announced today that it completed an agreement for the manufacturing of its COVID-19 vaccine in Africa. The landmark agreement, made between Johnson & Johnson’s Janssen Pharmaceuticals and South Africa-based Aspen SA Operations, allows for the first COVID-19 vaccine to be manufactured and made available by an African company for people living…
Johnson & Johnson pauses COVID-19 vaccine production in Dutch plant
Johnson & Johnson (NYSE:JNJ) has decided to temporarily suspend production of its COVID-19 vaccine in Leiden in the Netherlands to prioritize production of an investigational respiratory syncytial virus (RSV) vaccine, according to The New York Times. The plant will resume production of its COVID-19 vaccine in a matter of months, the paper reported. The company is…
Johnson & Johnson reaches opioid settlement with Colorado and Nevada
Johnson & Johnson (NYSE:JNJ) has reached a settlement agreement with Colorado and Nevada to put opioid-related allegations there to bed. Colorado will receive $385 million from Johnson & Johnson and the drug distributors McKesson (NYSE:MCK), AmerisourceBergen (NYSE: ABC) and Cardinal Health (NYSE:CAH). Nevada will receive nearly $285.2 million as part of the overall settlement, which is earmarked…
CDC’s ACIP deprioritizes Johnson & Johnson’s COVID-19 vaccine
CDC’s Advisory Committee on Immunization Practices (ACIP) voted 15 to 0 to prioritize the Pfizer-BioNTech and Moderna COVID-19 vaccines over Johnson & Johnson’s. One of the main reasons for the recommendation is a rare side effect associated with the Johnson & Johnson vaccine that results in low blood clots and blood-platelet levels. CDC officials revealed…
J&J joins Moderna and Pfizer in researching Omicron variant
Johnson & Johnson (NYSE:JNJ) has announced that it is collaborating with academic institutions internationally to gauge the effectiveness of its COVID-19 vaccine against Omicron and other SARS-CoV-2 variants. In particular, J&J said it is conducting research on blood serum from clinical trial volunteers who have received single or multiple doses of its COVID-19 vaccine. The…